Literature DB >> 11442641

Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.

M Gensana1, C Altisent, J A Aznar, P Casaña, F Hernández, J I Jorquera, M Magallón, M Massot, L Puig.   

Abstract

In order to determine the difference in reactivity of factor (F) VIII inhibitors against the FVIII/von Willebrand factor (vWF) complex and against vWF-deficient FVIII, we investigated a panel of 10 antibodies to FVIII from multitransfused individuals with severe haemophilia A and other pathologies. Immunoblotting of purified FVIII and purified thrombin-cleaved FVIII revealed that in all cases inhibitor epitopes could be localized in the heavy chain (A2 subunit) while in four cases they were also present in the light chain. One of the FVIII inhibitors remained unclassified. The effect on FVIII:C of purified IgG from inhibitor plasmas was tested against a high purity FVIII/vWF concentrate and a monoclonally purified FVIII concentrate with only trace contents of vWF, by two different functional assays. Our results suggest that for those inhibitors showing A2 plus light chain (LC) reactivity, the IgG concentration required to inhibit 50% of FVIII activity in vitro is higher for the FVIII/vWF complex than for the vWF-deficient FVIII. We conclude that there might be a protective role of vWF (at least in vitro) against FVIII inhibitors with A2 and LC subunit specificity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11442641     DOI: 10.1046/j.1365-2516.2001.00526.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  11 in total

1.  Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicity.

Authors:  Vivek S Purohit; Sathyamangalam V Balasubramanian
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

Review 2.  Immune tolerance induction for patients with severe hemophilia A: a critical literature review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-11       Impact factor: 2.300

Review 3.  Role of von Willebrand factor in the haemostasis.

Authors:  Flora Peyvandi; Isabella Garagiola; Luciano Baronciani
Journal:  Blood Transfus       Date:  2011-05       Impact factor: 3.443

4.  The von Willebrand factor from basic mechanisms to clinical practice.

Authors:  Augusto B Federici
Journal:  Blood Transfus       Date:  2011-05       Impact factor: 3.443

5.  A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors?

Authors:  Giovanni Di Minno; Antonio Coppola
Journal:  Blood Transfus       Date:  2011-05       Impact factor: 3.443

Review 6.  Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.

Authors:  Johannes Oldenburg; Sébastien Lacroix-Desmazes; David Lillicrap
Journal:  Haematologica       Date:  2015-02       Impact factor: 9.941

7.  Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.

Authors:  Vivek S Purohit; Karthik Ramani; Rita Sarkar; Haig H Kazazian; Sathyamangalam V Balasubramanian
Journal:  J Biol Chem       Date:  2005-02-23       Impact factor: 5.157

Review 8.  Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives.

Authors:  Zera Tellier; Marie-Hélène André; Benoît Polack
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

9.  On the versatility of von Willebrand factor.

Authors:  Antoine Rauch; Nikolett Wohner; Olivier D Christophe; Cécile V Denis; Sophie Susen; Peter J Lenting
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-07-10       Impact factor: 2.576

10.  Immune tolerance induction in patients with severe hemophilia A with inhibitors.

Authors:  Ji Eun Ryu; Young Shil Park; Ki Young Yoo; Kyoo Duck Lee; Yong-Mook Choi
Journal:  Blood Res       Date:  2015-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.